SynthesisFrontiers in oncology2026
From etiology to precision oncology: a systematic review of the causes and evolving treatments of prostate cancer.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer remains one of the most frequently diagnosed malignancies and a leading cause of cancer-related mortality among men globally. Its development is driven by a complex interaction of genetic susceptibility, molecular alterations, hormonal signaling, environmental exposures, and lifestyle-related factors. This systematic review synthesizes current evidence on the etiological mechanisms and evolving therapeutic landscape of prostate cancer. Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Literature published between January 2010 and December 2025 was searched in PubMed, Scopus, and Web of Science databases. Eligible studies included original research, clinical studies, translational studies, and experimental investigations evaluating prostate cancer etiology, molecular mechanisms, risk factors, biomarkers, or therapeutic interventions. Results: The review included 29 studies encompassing epidemiological cohorts, clinical studies, genomic analyses, tissue-based investigations, and preclinical experimental studies. Evidence demonstrated that prostate cancer etiology involves multiple interconnected pathways, including androgen receptor signaling, DNA repair alterations, genomic instability, chromatin remodeling, metabolic reprogramming, and inflammatory mechanisms. Genetic variants, including single nucleotide polymorphisms and polygenic risk scores, were associated with disease susceptibility, aggressiveness, treatment response, and toxicity outcomes. Therapeutic advances included optimization of androgen deprivation therapy, novel androgen receptor pathway inhibitors, chemotherapy, radiotherapy personalization, bone-targeted therapies, PSMA-directed radioligand therapy, and emerging immunotherapeutic approaches. Biomarker-driven strategies, including genomic classifiers and molecular signatures, showed potential for improving risk stratification and individualized treatment selection. Conclusion: Prostate cancer is a biologically heterogeneous disease requiring integrated approaches that combine molecular understanding with clinical decision-making. Recent advances in precision oncology have expanded therapeutic options beyond conventional treatment paradigms, enabling more personalized management strategies. However, further research is required to improve representation of diverse populations, validate biomarkers across different ethnic groups, and optimize the clinical implementation of emerging targeted and immune-based therapies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261435105.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.